The Role of Spirituality in Addiction Medicine

Spirituality Enters the Textbook

Galanter’s 2021 contribution to Springer’s Textbook of Addiction Treatment represents a significant institutional moment: a major academic publisher, in a standard medical reference text, devotes a full chapter to spirituality as a clinical modality in addiction treatment. This is not a fringe publication or an editorial opinion; it is a systematic review of evidence published in the format that medical professionals consult when determining treatment standards. The message is clear: the evidence for spirituality’s therapeutic role in addiction is now substantial enough that its exclusion from mainstream treatment represents a gap in care rather than an exercise in scientific rigor.

The Biomedical Resistance

Galanter addresses directly the institutional resistance to incorporating spirituality into addiction medicine. The resistance has deep roots. The biomedical model of addiction — which frames the disorder as a chronic brain disease driven by neurochemical dysregulation — has no conceptual category for spiritual experience. If addiction is a dopamine problem, then treatment is a dopamine solution: medications, behavioral conditioning, cognitive restructuring. Spirituality, in this framework, is at best an irrelevant complication and at worst a pre-scientific distraction. Galanter argues that this resistance is no longer defensible on empirical grounds. The evidence from outcome studies, neuroimaging research, and large-scale epidemiological surveys consistently demonstrates that spiritual engagement predicts recovery outcomes in ways that cannot be reduced to social support, expectancy effects, or placebo.

The Neurobiological Bridge

Galanter’s most innovative contribution is his attempt to identify the neurobiological mechanisms through which spiritual experience produces therapeutic change. He proposes that spiritual engagement activates the same neural systems involved in social bonding (oxytocin, endogenous opioids), reward processing (mesolimbic dopamine), and stress regulation (cortisol modulation) — systems that addiction hijacks and that recovery must restore. This model does not reduce spirituality to neurobiology; rather, it demonstrates that spiritual experience has neurobiological correlates that are clinically relevant and empirically measurable. The soul’s encounter with the sacred, whatever its ontological status, produces measurable changes in the same brain systems that addiction has disordered.

Jung’s Prescription, Eighty Years Later

For the depth psychological tradition, Galanter’s chapter is the institutional fulfillment of a conversation that began in 1961, when Jung wrote to Bill Wilson that the alcoholic’s craving was “the equivalent, on a low level, of the spiritual thirst of our being for wholeness, expressed in medieval language: the union with God.” Jung prescribed what the medical establishment of his time could not accommodate: a treatment that addressed the spiritual dimension of the disorder. Galanter, eighty years later, provides the evidence base that makes Jung’s prescription clinically actionable. The alcoholic’s craving is a spiritual thirst; the evidence now demonstrates that spiritual engagement quenches it in ways that medication and behavioral modification alone cannot. The depth tradition’s understanding of addiction — as a misdirected quest for the numinous, a failed attempt at self-transcendence — is no longer a theoretical position. It is an empirically supported clinical framework.